Orphan Drugs part 4: Fixing the System

The video discusses the orphan drug act, highlighting its role in encouraging research for rare diseases but also its exploitation by companies to increase drug prices. Proposed reforms include reducing exclusivity periods and limiting tax credits. Despite potential changes, high prices persist due to patents and lack of competition. Global examples like Sweden show resistance to high prices, but the U.S. struggles with similar measures. The video concludes with a call for reform and support for the show.

What new insight or understanding did you gain from this video?